Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Short-course DAA therapy may prevent hepatitis transmission in transplant patients

Key clinical point: A short course of direct-acting antiviral therapy combined with ezetimibe prevented or rapidly cured hepatitis C virus infection in transplant recipients receiving organs from infected donors.

Major finding: Sustained virologic response was seen in all patients by 12 weeks.

Study details: Reported results for 16 hepatitis C virus–infected donors and 25 recipients listed for heart, lung, kidney, or kidney-pancreas transplant.

Disclosures: Dr. Feld reported disclosures related to Abbvie, Abbott, Enanta Pharmaceuticals, Gilead, Janssen, Merck, and Roche.

Citation:

Feld JJ et al. The Liver Meeting 2019, Abstract 38.